Keymed Biosciences (HKG:2162) expects to report a profit of at least 1.2 billion yuan for the first half of 2026, compared with a loss of about 79 million yuan a year earlier, according to a Wednesday filing with the Hong Kong bourse.
The company attributed the turnaround to an upfront payment from the sale of its minority stake in Ouro Medicines, milestone payments from AstraZeneca tied to CMG901, strong Kangyueda sales, and tighter cost controls.